Skip to main content
. 2015 Dec 22;7(4):4632–4646. doi: 10.18632/oncotarget.6728

Figure 2. RKIP and NICD are inversely expressed in human cervical and stomach cancer tissues.

Figure 2

(A, B) RKIP and NICD expression in human cervical cancer. (A) Proteins were extracted from normal (patients #1–3) and cancerous (patients #4–11) human cervical tissues. Total proteins (30 μg) were subjected to immunoblot analysis. (B) Expression of each protein (RKIP or NICD) was quantified by densitometric scans and represented graphically. *p < 0.05 compared to normalized controls. (C, D) RKIP and NICD expression in human stomach cancer. (C) Proteins were extracted from pairs of tumorous and adjacent non-tumorous tissues of nine human stomach cancer patients (patients #1–9) with three different TNM stages (stage 1: patients #1–4, stage 2: patients #5–7, and stage 3: patients #8–9). (D) RKIP and NICD expression in stomach cancer specimens (indicated by “C”) were quantified followed by normalization to the expression of each protein, respectively, in matched adjacent non-tumorous tissues (indicated by “N”) and represented graphically. *p < 0.05 compared to normalized controls. (E, F) Expression of RKIP and NICD in YCC gastric cancer clones (human advanced gastric cancer cell lines). (E) Nine YCC clones (#3, 6, 7, 9, 10, 16, 18, 21, and 36) were subjected to immunoblot analyses. (F) The expression levels of RKIP and NICD in YCC clones were quantified and represented graphically. β-actin was used as loading control. All data indicate the mean values ± S.D. of at least three independent experiments. *p < 0.05.